A FORMAL SYNTHESIS OF (+)MILBEMYCIN  $\beta_3^1$ : A WITTIG APPROACH

Raymond Baker\*, Mary J. O'Mahony and Christopher J. Swain

Department of Chemistry, The University, Southampton SO9 5NH, England

Abstract: A new route has been established to generate the  $C_{14}$ - $C_{15}$  trisubstituted double bond of milbemycin  $\beta_3$  by reaction of a Wittig reagent with the appropriate spiroacetal aldehyde. The product of this reaction, after conversion to the iodide and enantiospecific alkylation to generate the  $C_{12}$  methyl group, has been elaborated to an intermediate previously involved in a total synthesis of milbemycin  $\beta_3$ .

The milbemycins  $^1$  and avermectins  $^2$  have been the target of considerable synthetic endeavour, and to date several total syntheses of milbemycin  $\beta_3$  have been reported  $^3$ ,  $^4$ . There have also been several reports of studies towards the preparation of structural sub-units of the more complex milbemycins and avermectins  $^5$ . In this communication we describe an alternative route to the spiroacetal moiety of milbemycin  $^3$  and an alternative strategy for its incorporation into the macrolide ring, a strategy which would also allow a facile entry into the avermectin series.

The starting point for this synthesis was the readily available (S)-methyl 3-hydroxy-2-methylpropionate ( $\underline{1}$ ). Sequential protection of the alcohol as its THP ether and reduction of the ester gave the alcohol ( $\underline{2}$ ) in 95% yield. Swern oxidation gave the corresponding aldehyde ( $\underline{3}$ ), chelation controlled cuprate attack then gave the desired threo product ( $\underline{4}$ ) as the major product (>20:1) in 90% yield. The secondary alcohol was then protected as its benzyl ether ( $\underline{5}$ ), acid catalysed removal of the THP

Avermectin A<sub>2b</sub> R = oleandrosyl-oleandrosyl

Milbemycin  $\beta_3$ 

Reagents: i)DHP/Et<sub>2</sub>O/CSA; ii)LiAlH<sub>4</sub>/Et<sub>2</sub>O; iii)DMSO/COCl<sub>2</sub>; iv)NEt<sub>3</sub>; v)Me<sub>2</sub>CuLi/Et<sub>2</sub>O -20°C; vi)NaH/THF; vii)PhCH<sub>2</sub>Br; viii)MeOH/H<sup>+</sup>; ix)Ph<sub>3</sub>P=CBr<sub>2</sub>/THF 0°C; x)2 x  $\underline{n}$ -BuLi/THF -80°C.

protecting group and subsequent Swern oxidation afforded the aldehyde  $(\underline{6})$  in 70% overall yield. The aldehyde was then converted,  $\underline{\text{via}}$  the dibromide  $(\underline{7})$ , to the acetylene  $(\underline{8})$ ,  $[\alpha]^{20}_{D} = -8.4^{\circ}$  (c 1.5,  $\text{CH}_2\text{Cl}_2$ , bp 58-60°C at 17 mm Hg, (60%) (shown to be >95% ee by preparation of the MTPA ether).

The acetylene (8) was coupled to the lactone (9)7 and converted to the known spiroacetal (10) by the procedure reported previously<sup>7</sup>. Treatment with one equivalent of p-toluenesulphonyl chloride in pyridine yielded the primary tosylate selectively (70%); the secondary alcohol was then protected as its t-butyldiphenylsilyl ether (11) (100%). Nucleophilic displacement of the tosylate by NaCN in DMSO (80°C) yielded the corresponding nitrile (80%). Dibal reduction to the aldehyde and subsequent Wittig reaction gave the  $\alpha,\beta$ -unsaturated ester (12)\* in a 60% overall yield;  $[\alpha]^{D}$ = +38° (c 0.4,  $CH_2Cl_2$ );  $v_{max}$  1710 (C=0), 1650, 1450, 1380, 1110, 830, 740, 705 cm<sup>-1</sup>;  $\delta_{\rm H}$  (360MHz) (CDCl<sub>3</sub>), 7.6 (4H, m, Ar), 7.3 (6H, m, Ar), 6.77 (1H, dd, J=2H,  $H_1$ ), 4.14 (1H, m,  $H_f$ ), 4.1 (2H, q, J=7Hz,  $\sim C_{H2}\sim CH_3$ ), 3.3 (1H, m,  $H_h$ ), 3.0 (1H, dq, J=6,11  $H_a$ ), 2.2 (2H, m,  $2xH_i$ ), 1.85 (1H, dd,  $H_e$ ), 1.79  $(3H, s, Me_k), 1.65$  (1H, ddd,  $H_g$ ), 1.4-1.6 (5H, m, H,  $2xH_g$ ,  $2xH_d$ ), 1.26 (3H, t, J=7, MeCH<sub>2</sub>), 1.27 (2H, m, H<sub>q</sub>, H<sub>e</sub>), 1.05 (9H, s,  $\underline{t}$ -Bu), 0.95 (3H, d, J=6Hz,  $Me_a$ ), 0.75 (3H, d, J=7,  $Me_b$ ).

<sup>\*13</sup>C NMR indicates single double bond isomer.

Reagents: i)TsCl/pyr; ii)t-BuPh2SiCl/DMF/imidazole; iii)NaCN/DMSO/80°C; iv)Dibal/CH2Cl2; v)EtO2CC(Me)PPh3; vi)MeSO2Cl/pyr/DMAP; vii)NaI/THF; viii)LiAlH4/Et2O; ix)PhS-/MeOH; x)Oxone.

Dibal reduction yielded the key allylic alcohol  $(\underline{13})$  (65%), conversion to the very unstable allylic iodide  $(\underline{14})$  and subsequent alkylation of the oxazolidone  $(\underline{15})^8$  yielded the alkylated product  $(\underline{16})$  (80%) in which the stereochemistry of the remote methyl at  $C_{12}$  had been generated. In addition a small amount (15%) of another double bond isomer was isolated  $^{10}$ .

Reductive removal of the chiral auxiliary and a simple functional group modification then allowed the conversion to the sulphone  $(\underline{17})$  which has previously been incorporated into a total synthesis of (+) milbemycin  $\beta_3$ <sup>3</sup>.

This approach also provides a route to the avermectins. Oxidation of the allylic alcohol  $(\underline{13})$  to the unsaturated aldehyde followed by a directed aldol condensation would allow the introduction of the  $C_{13}$  oxygenation required for the avermectins (Scheme).

## References

- 1. H. Mishima, M. Kurabayashi, C. Tanura, S. Sato, H. Kuwano and A. Saito, Tetrahedron Lett., 1975, 711
- G. Albers-Schonberg, B.H. Arison, J.C. Chabala, A.W. Douglas,
   D. Eskola, M.H. Fisher, A. Lusi, H. Mrozik, J.L. Smith and
   R.L. Tolman, J.Amer.Chem.Soc., 1981, 103, 4216
- R. Baker, M.J. O'Mahony and C.J. Swain, <u>J.Chem.Soc., Chem.Commun.</u>, 1985, 1326
- S.R. Schow, J.D. Bloom, A.S. Thompson, K.N. Winzenberg and A.B. Smith III, J.Amer.Chem.Soc., 1982, 104, 4015; D.R. Williams, B.A. Barner, K. Nishitani and J.G. Phillips, J.Amer.Chem.Soc., 1982, 104, 4708; S.D. Street, C. Yeates, P. Kocienski and S.F. Campbell, J.Chem.Soc., Chem.Commun., 1985, 1386, 1388; S.V. Attwood, A.G.M. Barrett, R.E.A. Carr and G. Richardson, J.Chem.Soc., Chem.Commun., 1986, 479
- S. Hanessian, A. Ugolini and M. Therin, J.Org.Chem., 1983, 48, 4427;
   R. Baker, J.C. Head and C.J. Swain, J.Chem.Soc., Chem.Commun., 1985, 309;
   M. Prashad, B. Fraser-Reid, J.Org.Chem., 1985, 50, 1564;
   M.E. Jung and L.J. Street, J.Amer.Chem.Soc., 1984, 106, 8327;
   M.J. Hughs, E.J. Thomas, M.D. Turnbull, R.H. Jones and R.E. Warner, J.Chem.Soc., Chem.Commun., 1985, 755;
   M.T. Crimmens and J.G. Lever, Tetrahedron Lett., 1986, 27, 291;
   A.P. Kozikowski and K.E. Malony Huss, Tetrahedron Lett., 1985, 26, 5759
- 6. J.A. Scheider and W.C. Still, Tetrahedron Lett., 1980, 21, 1035
- R. Baker, R.H.O. Boyes, D.M.P. Broom, J.A. Devlin and C.J. Swain, J.Chem.Soc., Chem.Commun., 1983, 829
- D.A. Evans, M.D. Ennis and J.J. Mathre, <u>J.Amer.Chem.Soc.</u>, 1982, <u>104</u>, 1737
- 9. K. Mori and S. Senda, <u>Tetrahedron</u>, 1984, 41, 541
- D.A. Evans and R.L. Dow, <u>Tetrahedron Lett.</u>, 1986, <u>27</u>, 1007.
   (Received in UK 23 April 1986)